RxDoctor Payments Data

Katharine Ammons, MD

Internal Medicine · Rome, GANPI 1962562207

Payments from drug & device makers

$3,088in general payments, 2019–2025

Across 201 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$674
  • Pfizer$638
  • Lilly USA, LLC$401
  • Novo Nordisk$327
  • Abbott$207
  • Boehringer Ingelheim$146
  • plus $695 from 15 others

What the payments were for

  • Food & beverage$3,088100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,088 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$238,407
Medicare patients
738
Services billed
16,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide163$179,554
EliquisApixaban197$166,879
OzempicSemaglutide101$114,950
JanuviaSitagliptin Phosphate65$90,640
XareltoRivaroxaban61$70,408
LinzessLinaclotide62$46,991
JardianceEmpagliflozin40$41,605
VraylarCariprazine Hcl29$39,861
MyrbetriqMirabegron27$30,003
RybelsusSemaglutide23$26,758
FarxigaDapagliflozin Propanediol19$22,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,961
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen610$17,902
SavellaMilnacipran Hcl30$16,698
TrulicityDulaglutide14$16,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$401$195,983177 claims
PfizerEliquis$638$166,879197 claims
Novo NordiskOzempic, Rybelsus$327$141,708124 claims
AbbVieLinzess, Vraylar, Savella, Synthroid$674$110,510215 claims
Johnson & JohnsonXarelto$57$70,40861 claims
Boehringer IngelheimJardiance, Spiriva Respimat$146$51,60055 claims
Astellas Pharma US IncMyrbetriq$47$30,00327 claims
AstraZenecaFarxiga$84$22,19119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →